Publication:
Contact pathway in surgical and transcatheter aortic valve replacement

Simple item page
dc.contributor.authorMorena Barrio, María Eugenia de la
dc.contributor.authorCorral, Javier
dc.contributor.authorLópez García, Cecilia
dc.contributor.authorJiménez Díaz, Víctor Alonso
dc.contributor.authorMiñano, Antonia
dc.contributor.authorJuan-Salvadores, Pablo
dc.contributor.authorEsteve Pastor, María Asunción
dc.contributor.authorBaz Alonso, José Antonio
dc.contributor.authorRubio, Ana María
dc.contributor.authorSarabia Tirado, Francisco
dc.contributor.authorGarcía Navarro, Miguel
dc.contributor.authorGarcía Lara, Juan
dc.contributor.authorMarín, Francisco
dc.contributor.authorVicente, Vicente
dc.contributor.authorPinar, Eduardo
dc.contributor.authorCánovas López, Sergio
dc.contributor.authorMorena, Gonzalo de la
dc.contributor.departmentCirugía, Pediatría y Obstetricia y Ginecología
dc.date.accessioned2024-07-18T08:36:57Z
dc.date.available2024-07-18T08:36:57Z
dc.date.issued2022-07-22
dc.description© 2022 de la Morena-Barrio, Corral, López-García, Jiménez-Díaz, Miñano, Juan-Salvadores, Esteve-Pastor, Baz-Alonso, Rubio, Sarabia-Tirado, García-Navarro, García-Lara, Marín, Vicente, Pinar, Cánovas and de la Morena. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0. This document is the Published version of a Published Work that appeared in final form in Frontiers in Cardiovascular Medicine. To access the final edited and published work see https://doi.org/10.3389/fcvm.2022.887664
dc.description.abstractBackground: Aortic valve replacement is the gold standard treatment for severe symptomatic aortic stenosis, but thrombosis of bioprosthetic valves (PVT) remains a concern. Objective: To analyze the factors involved in the contact pathway during aortic valve replacement and to assess their impact on the development of thromboembolic complications. Methods: The study was conducted in 232 consecutive patients who underwent: transcatheter aortic valve replacement (TAVR, N = 155), and surgical valve replacement (SAVR, N = 77) (MUVITAVI project). Demographic and clinical data, outcomes including a combined end point (CEP) of thrombotic events, and imaging controls were recruited. Samples were collected 24 h before and 48 h after valve replacement. FXII, FXI and (pre)kallikrein were evaluated by Western Blot and specific ELISA with nanobodies. Results: The CEP of thrombotic events was reached by 19 patients: 13 patients presented systemic embolic events and 6 patients subclinical PVT. Valve replacement did not cause FXII activation or generation of kallikrein. There was a significant reduction of FXI levels associated with the procedure, which was statistically more pronounced in SAVR than in TAVR. Cases with reductions of FXI below 80% of basal values had a lower incidence of embolic events during the procedure than patients in whom FXI increased above 150%: 2.7 vs. 16.7%; p: 0.04. Conclusion: TAVR or SAVR did not significantly activate the contact pathway. A significant reduction of FXI, was observed, particularly in SAVR, associated with lower incidence of thrombotic events. These results encourage evaluating the usefulness and safety of FXI-directed antithrombotic treatments in these patients.es
dc.formatapplication/pdfes
dc.format.extent12es
dc.identifier.citationFront. Cardiovasc. Med. 9:887664
dc.identifier.doihttps://doi.org/10.3389/fcvm.2022.887664
dc.identifier.issnElectronic: 2297-055X
dc.identifier.urihttp://hdl.handle.net/10201/143186
dc.languageenges
dc.publisherFrontiers Media
dc.relationThis study was supported by the Sociedad Española de Cardiología: Proyecto FEC Investigación Clínica, 2017. CIBERCV (CB16/11/00385); Fundación Séneca (19873/GERM/15), CIBERER (ACCI18-04; ER19P5AC765/2019); Instituto de Salud Carlos III (PI21/00137); and Sociedad Española de Trombosis y Hemostasia (SETH: grupos emergentes). MM-B has a postdoctoral contract from University of Murcia, Spain.es
dc.relation.publisherversionhttps://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.887664/full
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectContact pathwayes
dc.subjectAortic valve replacementes
dc.subjectThrombosises
dc.subjectFactor XIes
dc.subjectFactor XIIes
dc.titleContact pathway in surgical and transcatheter aortic valve replacementes
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fcvm-09-887664.pdf
Size:
5.1 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos